0001140361-24-013497.txt : 20240315 0001140361-24-013497.hdr.sgml : 20240315 20240315160738 ACCESSION NUMBER: 0001140361-24-013497 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Colangelo Dominick CENTRAL INDEX KEY: 0001313403 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 24754768 MAIL ADDRESS: STREET 1: 1000 WINTER ST. STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml FORM 4 X0508 4 2024-03-13 0000887359 Vericel Corp VCEL 0001313403 Colangelo Dominick 64 SIDNEY STREET CAMBRIDGE MA 02139 true true President and CEO true Common Stock 2024-03-13 4 M 0 17500 3.02 A 212370 D Common Stock 2024-03-13 4 S 0 17500 44.67 D 194870 D Common Stock 2024-03-14 4 M 0 17500 3.02 A 212370 D Common Stock 2024-03-14 4 S 0 17500 44.02 D 194870 D Stock Option (Right to Buy) 3.02 2024-03-13 4 M 0 17500 0 A Common Stock 17500 297500 D Stock Option (Right to Buy) 3.02 2024-03-14 4 M 0 17500 0 A Common Stock 17500 280000 D These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 1, 2023. These options, representing the right to purchase 440,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. These options, which were awarded on January 5, 2015, would otherwise expire and become forfeitable on January 5, 2025. /s/ Sean Flynn, as Attorney-in-Fact for Dominick C. Colangelo 2024-03-15